{"acquisitions":[],"changes":[],"country":"US","description":"Endovascular Engineering develops the Helo Thrombectomy Platform, a system for non-surgically removing blood clots from pulmonary arteries and veins. It serves clinicians treating pulmonary embolism and venous thromboembolism. Its differentiator is a patented dual-action design combining mechanical clot disruption with aspiration.","domain":"e2.bio","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":"endovascularengineering","githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.451967,"lng":-122.177992,"location":"Menlo Park CA","multiples":[],"name":"Endovascular Engineering","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":80000000,"connectionsAmong":[],"currency":"USD","date":"2026-04-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"e2-bio-2026-04-01-series-c","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"e2-bio","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"e2.bio","retrievedAt":"2026-05-02","status":"self-reported","url":"https://e2.bio"},{"fact":"description","publisher":"e2.bio","retrievedAt":"2026-05-02","status":"self-reported","url":"https://e2.bio"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":150000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}